TEVA

28°

Weather

YnetGlobal Channels

Sites & Sources

more channels

Contact

TEVA

Moody’s upgrades Teva to investment grade, citing growth and continued debt reduction

Ratings agency raises Israeli drugmaker to Baa3 with a stable outlook, pointing to stronger earnings, improving margins, solid cash flow and expectations that debt will continue to fall over the next 12 to 18 months

ynet Global | 08.11.26

Teva advances experimental vitiligo drug after encouraging early results

Israeli drugmaker says TEV-408, an anti-IL-15 antibody designed for quarterly dosing, improved skin pigmentation in an early-stage study and will move into Phase 2b development later this year

ynet Global | 07.07.26

Pharma giant Teva to cut 250 jobs at Israel plant

Layoffs at Teva Tech in Ramat Hovav are part of a global restructuring of TAPI, Teva’s active pharmaceutical ingredients unit, as the company weighs a possible sale

Navit Zomer | 06.10.26

Teva regains investment-grade rating from Fitch

Fitch points to expected growth from drugs including Austedo and Ajovy; Teva is still rated below investment grade by S&P Global Ratings, at BB+ with a stable outlook, and by Moody’s, at Ba1 with a positive outlook

ynet Global | 05.18.26

ריצ'רד פרנסיס, נשיא ומנכ"ל טבע, במפגש העיתונאים

Teva resumes acquisitions with $900 million Emalex deal after decade-long hiatus

Teva will pay $700 million upfront and up to $200 million more for Emalex, which develops a Tourette syndrome treatment granted orphan drug status; the deal comes as the company reports $4 billion in quarterly revenue and $369 million in net profit, beating forecasts

Navit Zomer | 04.29.26

From Netanya labs to global race: Teva develops antibody targeting celiac and autoimmune diseases

Backed by up to $500 million deal, Teva advances experimental antibody for celiac and vitiligo, aiming to stop autoimmune disease at its source; researcher offers rare look inside complex path from lab to patients

Eitan Gefen | 04.07.26

Teva shares slide as 2026 forecast disappoints despite strong 2025 earnings

Israel-based pharma giant posts $17.3 billion in 2025 revenue and 19% profit growth, but stock falls on lower-than-expected 2026 outlook, even as CEO touts pipeline potential and billion-dollar quarter from flagship drugs

Navit Zomer | 01.28.26

Teva’s billion-dollar bet to treat celiac and vitiligo

Teva is investing up to $500 million in a new antibody it hopes can transform treatment for vitiligo and celiac disease, two autoimmune conditions with limited options and major unmet medical needs

Tzur Gueta | 01.13.26

Teva, Royalty Pharma announce $500M deal to advance autoimmune drug

New partnership aimed at advancing Israeli pharma giant's anti-IL-15 drug for autoimmune diseases; CEO Richard Francis to detail growth strategy and pipeline progress at J.P. Morgan Healthcare Conference on Jan. 13

ynet Global | 01.12.26

Teva launches new global innovation program, will fully fund startup pilots

Teva is opening a call for startups in Israel and abroad as part of its new Rise program, offering full funding for pilots, rapid integration and support across seven innovation domains, in a move to accelerate drug development and supply-chain efficiency

Tal Shahaf | 11.20.25

רופאה ד"ר ריטה סגנטיני והאחות ג'וליה קקאצ'י זרקו תרופות של טבע באיטליה

Italian Jewish Medical Association demands action after hospital staff film anti-Israel Teva drug disposal

Dr. Daniel Radzik says letters to Health Minister and hospital were necessary to force apology after Tuscany medical staff filmed anti-Israel video; calls incident part of growing antisemitic climate across Europe; 'Medicines must not be used as tools of political or ideological dispute'

Ynetnews | 08.21.25

Outrage in Italy after medical staff seen discarding Israeli-made Teva medications

Protest targeting Israeli pharmaceutical giant Teva comes amid rising anti-Israel sentiment in Italy; pair later apologize, calling it 'a symbolic gesture for peace' and claiming no medicine actually discarded

Daniel Bettini | 08.20.25

Acamol, a household name in Israel, will now be made in Ulm; while prices remain steady, capsule counts will change; company says Israeli staff will focus on complex drugs and no jobs will be cut

Navit Zomer | 08.05.25

Trump’s drug price cuts hit Teva at a tough time

Israeli pharmaceutical giant recently announced plans to cut 8% of its global workforce and U.S. push for lower drug prices could trigger further layoffs

Sophie Shulman | 05.13.25

Hundreds of Israeli workers could be affected by Teva layoffs

Analysis: The pharmaceutical giant has announced an 8% cut in its workforce to improve efficiency; About 300 employees in Israel are expected to be laid off. While investors are pleased with the promise of reaching a 30% operating profit, employees may find that this is just the first 'big step' in a series of cuts

Sophie Shulman, Calcalist | 05.08.25

Hot Tags

Today

This Week

This Month

accident Adolf Eichmann AI Air Defense System All Caps Altalena Amazon Animals Anthropic Antisemitism

Hot Tags

Today

This Week

This Month

accident Adolf Eichmann AI Air Defense System All Caps Altalena Amazon Animals Anthropic Antisemitism